These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36091147)

  • 61. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
    Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
    Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?
    Giraudo A; Sabatier R; Rousseau F; De Nonneville A; Gonçalves A; Cecile M; Braticevic C; Viret F; Seguin L; Kfoury M; Naudet D; Hamon M; Tassy L
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791919
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis.
    Qin S; Xv Z; Chen X; Wang S; Lu H; Li J; Guo X; Yang J; Liu C; Wang Y; Wang H
    Front Oncol; 2023; 13():1072634. PubMed ID: 36910649
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis.
    Wang Y; Xu H; Han Y; Wu Y; Wang J
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884431
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis.
    Huang Q; Zheng Y; Gao Z; Yuan L; Sun Y; Chen H
    J Cancer; 2021; 12(4):1133-1143. PubMed ID: 33442411
    [No Abstract]   [Full Text] [Related]  

  • 68. PI3K/Akt/mTOR inhibitors in breast cancer.
    Lee JJ; Loh K; Yap YS
    Cancer Biol Med; 2015 Dec; 12(4):342-54. PubMed ID: 26779371
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
    Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T; Becerra C; Kalinsky K; Moore KN; Manuel AM; Lithio A; Price GL; Chapman SC; Litchfield LM; Goetz MP
    Front Oncol; 2021; 11():810023. PubMed ID: 35223458
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
    Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
    Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis.
    Wei X; Song M; Huang C; Yu Q; Jiang G; Jin G; Jia X; Shi Z
    Front Oncol; 2023; 13():1062885. PubMed ID: 36845678
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
    Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
    Howie LJ; Singh H; Bloomquist E; Wedam S; Amiri-Kordestani L; Tang S; Sridhara R; Sanchez J; Prowell TM; Kluetz PG; King-Kallimanis BL; Gao JJ; Ibrahim A; Goldberg KB; Theoret M; Pazdur R; Beaver JA
    J Clin Oncol; 2019 Dec; 37(36):3475-3483. PubMed ID: 31560580
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.
    Giuliani J; Bonetti A
    J Oncol Pharm Pract; 2020 Sep; 26(6):1486-1491. PubMed ID: 32576084
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.
    Chia S; Gandhi S; Joy AA; Edwards S; Gorr M; Hopkins S; Kondejewski J; Ayoub JP; Califaretti N; Rayson D; Dent SF
    Curr Oncol; 2015 Feb; 22(1):33-48. PubMed ID: 25684987
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options.
    Elfgen C; Bjelic-Radisic V
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885105
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
    O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
    Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
    [TBL] [Abstract][Full Text] [Related]  

  • 78. RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.
    Petracci F; Abuin GG; Pini A; Chacón M
    Ecancermedicalscience; 2020; 14():1058. PubMed ID: 32582373
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.
    Daniell KM; Bardia A; Sun F; Roberts SA; Brunelle CL; Gillespie TC; Sayegh HE; Naoum GE; Juric D; Isakoff SJ; Fitzgerald DM; Taghian AG
    Breast Cancer Res Treat; 2019 Jun; 175(3):649-658. PubMed ID: 30919166
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
    Miricescu D; Totan A; Stanescu-Spinu II; Badoiu SC; Stefani C; Greabu M
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.